Compare YSG & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSG | TOVX |
|---|---|---|
| Founded | 2016 | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 889.0M | 7.3M |
| IPO Year | 2020 | 2006 |
| Metric | YSG | TOVX |
|---|---|---|
| Price | $4.35 | $0.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 234.7K | ★ 10.7M |
| Earning Date | 02-24-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $571,300,568.00 | N/A |
| Revenue This Year | $28.96 | N/A |
| Revenue Next Year | $16.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.59 | N/A |
| 52 Week Low | $3.01 | $0.17 |
| 52 Week High | $11.57 | $2.03 |
| Indicator | YSG | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 41.76 | 48.84 |
| Support Level | $4.00 | $0.19 |
| Resistance Level | $4.45 | $0.26 |
| Average True Range (ATR) | 0.24 | 0.03 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 70.00 | 56.55 |
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.